Skip to site menu Skip to page content

Daily Newsletter

25 July 2023

Daily Newsletter

25 July 2023

Patents signal: Johnson & Johnson leads assignees for Q2 2023

Each week, Medical Device Network journalists analyse data on patent filings and grants that illustrate innovation trends in our sector.…

Catherine Longworth July 25 2023

Each week, Medical Device Network journalists analyse data on patent filings and grants that illustrate innovation trends in our sector. These patent signals show where the leading companies are focusing their research and development investment, and why. We uncover key innovation areas in the sector and the themes that drive them.  

This new, thematic patents coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.  

This week, we examine GlobalData patent analytics of assignees and technology trends for patent filings in the medical device landscape over Q2 2023. Johnson & Johnson topped the number of patents filed during this period, followed by Medtronic and Philips.

The data shows that New Jersey-headquartered Johnson & Johnson had a total of 1,374 publications, 752 applications and 589 grants.

Grants here refer to approved documents by the patent office after document examination and criteria satisfaction.

Most of the patents filed were related to general surgery devices, diagnostic imaging and healthcare I.T.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close